Navigation Links
Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011

PARIS, Sept. 7, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced that its nuclease production capacity has increased ten-fold in 2011, significantly reducing manufacturing costs. Industrialization of the nuclease manufacturing gives Cellectis bioresearch, the genome customization specialist and commercial subsidiary of Cellectis, the potential to supply the technology to approximately 300,000 academic and industrial research laboratories throughout the world. Previously the technology was only used by large industrial groups and laboratories with significant financial resources.

In the last three years, Cellectis has invested significantly to increase its production capacities, growing from 20 nucleases produced in 2008 to a capacity of 7,200 units in 2011, a rate that is expected to continue through 2012.

The use of nucleases by Cellectis' initial customers has demonstrated significant advantages over competitive technologies for creating cell lines for high throughput screening, in a number of diverse applications.

The use of nucleases may also allow, in a near future, researchers to consider Whole Genome Engineering for all kinds of species, and for any application. It is revolutionary change for research, which previously required a gene-by-gene approach.

"Thanks to this dramatic increase in its production capacity, Cellectis is in a very good position for the emerging Whole Genome Engineering calls for tender," said Andre Choulika, Chairman and CEO of Cellectis. "It represents a major technological step-change that we've been targeting for the last 10 years: the high throughput Whole Genome Engineering."

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at:

Follow Cellectis on twitter:


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
6. Cellectis Unveils Its New Corporate Website
7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):